ENTRUST Bolsters Edoxaban As VKA Alternative In AF Patients
Daiichi drug shows non-inferiority to standard antithrombotic regimen in atrial fibrillation patients, adding to evidence supporting Factor Xa inhibitor's use.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.